key: cord-0034580-dc5263ri authors: Berger, Dietmar P.; Engelhardt, Rupert; Henß, Hartmut; Scheele, Jürgen; Müller, Claudia I.; Göbel, Alexandra; Lubrich, Beate; Kaskel, Anna-Katharina; Veelken, Hendrik; Potthoff, Karin; Waesch, Ralph; Martens, Uwe; Schmoor, Claudia; Maier-Lenz, Herbert; Müller, Antonia title: Pharmacology and Pharmacotherapy date: 2008 journal: Concise Manual of Hematology and Oncology DOI: 10.1007/978-3-540-73277-8_3 sha: b512635fc99868f8296a4450660807dc9dac74a3 doc_id: 34580 cord_uid: dc5263ri nan • "Multidrug resistance (MDR)" via P-glycoprotein (P170, membrane protein, 170 kDa): ATPdependent transport of naturally occurring toxins out of the cell → inhibition of effect of anthracyclines, vinca alkaloids, taxanes, epipodophyllotoxins. Physiological expression of P170 in gastrointestinal tract, biliary ducts, kidney. Induction of expression in malignant cells by cytostatics. • Topoisomerase II resistance due to changes of the target molecule DNA-topoisomerase II → reduced effect of epipodophyllotoxins and anthracyclines. • Antimetabolite resistance: altered expression of target enzymes (e.g., thymidylate synthase TS, dihydrofolate reductase DHFR) → reduced effect of 5-FU, methotrexate, etc. • Glutathione (GSH) and glutathione-S transferase (GST): reduced glutathione and GST contribute to intracellular detoxification of alkylating agents and platinum compounds → reduced effect caused by increased intracellular GSH levels or increased expression of GST. • O6-Alkyltransferase (AT): DNA-repairing enzyme, corrects alkylation of O6 position of guanine induced by nitrosoureas → reduces effect of carmustine, lomustine, nimustine. . Basic Principles of Chemotherapy N,N,N' ,N' ,N,N-hexamethyl-1,3,5-triazine-2,4,6-triamine, hexamethylmelamine DNA alkylation and intercalation, inhibition of DNA and RNA synthesis • Oral administration after food, 260-320 mg/m2/day (8-12 mg/kg/day) p.o., in 3-4 daily divided doses, for 14-21 days, repeat every 4-6 weeks; in combination therapy 150-200 mg/m2/ day (4 mg/kg/day) • Dose modification 7 Chap. 3.2.4 • ATTN: cimetidine and barbiturates alter effect (t½) due to cytochrome P450 induction or inhibition • BEFORE TREATMENT: full blood count, liver and renal function tests, neurological evaluation Arsenic trioxide, As2O3 Induction of differentiation, apoptosis and DNA fragmentation of PML-RARα-positive cells in acute promyelocytic leukemia, antiangiogenetic effect • Kinetics: intravenous administration, intravascular binding to hemoglobin (96%), half-life: t½ 12 h • Metabolism: hepatic degradation (90%), renal excretion (10%) • Bone marrow: myelosuppression (15%), with anemia, neutropenia, thrombocytopenia • Cardiovascular: tachycardia (50%), QT prolongation, AV block, ventricular arrhythmia (torsades de pointes) • Gastrointestinal: nausea, vomiting, mucositis, sore throat, diarrhea, abdominal pain (50%), gastrointestinal bleeding (rare), weight loss • Liver: elevated transaminases, impaired liver function, hyperglycemia • Kidney: hypokalemia, hypocalcemia, hypomagnesemia, impaired renal function (rare) • Skin: dermatitis, erythema, urticaria, pruritus, cutaneous bleeding (ecchymosis, petechiae (rare)), epistaxis (25%) • Nervous system: headache (60%), insomnia, anxiety disorders, arthralgia, paresthesias • Local toxicity: phlebitis, local edema, erythema • Other: "differentiation syndrome": fever, leukocytosis, cough, dyspnea, hypoxia, thoracic pain, pleural / pericardial effusions, hypotension, edema. Treatment with corticosteroids (e.g., dexamethasone 10 mg twice a day). Coagulation disorders (rare), DIC (disseminated intravascular coagulation) • Severely impaired liver or renal function • Electrolyte disturbances, QT prolongation (especially > 500 ms), AV conduction disorders Enzyme derived from Escherichia coli or Erwinia carotovora. Covalently linked with polyethylene glycol (PEG) to form PEG-asparaginase • Catalyses hydrolysis of L-asparagine to L-asparaginic acid and ammonia, intravascular depletion of asparagine and inhibition of protein synthesis of malignant lymphatic cells (normal cells are capable of asparagine synthesis by induction of asparagine synthetase) • Cell-cycle-specific: G1 phase • Kinetics: terminal half-life: t½ 8-30 h (depending on dose and compound), t½ prolonged to 3-6 days with PEG-asparaginase • Elimination: metabolic degradation (proteolysis) • Gastrointestinal: moderate nausea / vomiting (60%), mucositis, loss of appetite, diarrhea (rare) • Liver / pancreas: impaired liver function, elevated transaminases (50% of patients), hepatitis, pancreatitis, hyperglycemia, impairment of clotting factor synthesis (especially fibrinogen and antithrombin III), thromboembolic events, hemorrhage • Kidney: transient increase of serum creatinine and uric acid, acute renal failure (rare) or severely impaired renal function (rare) • Nervous system: acute: reversible encephalopathy in 25-50% of patients: lethargy, somnolence, confusion; chronic: psychotic organic brain syndrome • Other: dose-limiting allergic reactions: fever, chills, urticaria, skin reactions, bronchospasm, laryngospasm, asthma, anaphylactic shock. Reduced immunogenicity with PEG-asparaginase • Known intolerance • Pancreatitis • Impaired liver function, pre-existing coagulation disorders Approved indications: ALL Other areas of use: AML, NHL, CML in lymphatic blast crisis, CLL • L-Asparaginase 5,000-20,000 IU/m2/day i.v. for 10-20 days, i.m. application possible • PEG-asparaginase: 2,500 IU/m2/day i.v. every 14 days, i.m. application possible • Dose modification 7 Chap. 3.2.4, incompatibility 7 Chap. 3.2.6, stability 7 Chap. 3.2.7 • ATTN: coagulation disorders: if fibrinogen < 0.8 g/l or ATIII < 70%, give fresh frozen plasma (FFP) or ATIII. If fibrinogen < 0.5 g/l or Quick's test < 30%, end treatment. Allergic Reactions: close observation of the patient, monitor blood pressure. Allergic reactions must be treated acutely with antihistamines and corticosteroids. Change preparation if necessary (allergic reactions commonly due to bacterial impurities) • BEFORE TREATMENT: full blood count, liver and renal function tests, blood glucose, clotting studies. Pretherapy intradermal skin test (dose: 2 IU) to exclude possible hypersensitivity is recommended • 75 mg/m2/day s.c. days 1-7 every 4 weeks, or 105 mg/m2/day s.c. days 1-5 every 4 weeks. Intravenous application possible • ATTN: azacytidine may be embryotoxic, teratogenic, and mutagenic in humans. Appropriate precautions should be taken to avoid pregnancy and fathering. Monitoring of blood counts, liver enzymes, and renal function required • BEFORE TREATMENT: full blood count, liver and renal function tests, electrolytes Pharmacology and Pharmacotherapy Gamma- (1-methyl-5-bis(beta-chloroethyl) aminobenzimidazole-(2)-butyric acid, alkylating agent, nitrogen mustard derivative Cross-linking of DNA single and double strands by alkylation, DNA-protein and protein-protein linking Decitabine (5-aza-2'-deoxycytidine) 4-Amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one, pyrimidine nucleoside analog • Inhibition of DNA methyltransferase after incorporation into DNA • Causes demethylation and hypomethylation of DNA, potentially with functional changes of genes regulating differentiation, proliferation, and apoptosis • Skin: exanthema, urticaria, alopecia, delayed tissue reaction in a previously irradiated site ("radiation recall reaction"), nail changes, hyperpigmentation (rare); reversible erythrodysesthesia with liposome-encapsulated doxorubicin • Local toxicity (extravasation 7 Chap. 9.9): causes severe necrosis • Other: fever, allergic reactions, red urine • Cardiac disease (arrhythmias, myocardial infarction, coronary heart disease, heart failure) • Severely impaired liver function, acute infections Approved indications: solid tumors (e.g., small cell lung cancer, breast cancer, ovarian cancer, endometrial cancer, bladder cancer, thyroid cancer, sarcomas, Wilms' tumor), malignant lymphomas (e.g., Hodgkin's disease, multiple myeloma, NHL), AML, ALL • Folinic acid increases cytotoxic effect of 5-FU • Combination therapy 5-FU + folinic acid: always administer folinic acid before 5-FU Lenalidomide 3-(4-Amino-1-oxo 1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione, thalidomide analog Mechanism of action not fully characterized. Proposed mechanisms include: • Immunomodulation: immunosuppressive properties, proinflammatory cytokines ↓, anti-inflammatory cytokines ↑, tumor necrosis factor ↓, cyclooxygenase-2 (COX-2) ↓ • Anti-angiogenic properties • Direct antineoplastic / cytotoxic activity in cells of lymphatic origin • Standard dose: 1 × /day in the first week to the involved skin area, thereafter twice a day, 1-2 drops per 10 cm2, not more than 5 ml/day in total • Hormone therapy or chemotherapy may be given concurrently Every cytostatic treatment carries the risk of adverse and potentially life-threatening effects. Therefore, it is imperative to observe general treatment guidelines as well as specific precautions for certain cytostatics. The procedures listed below are mandatory in all patients before and during cytostatic treatment. However, this list is not exhaustive. Additional measures may be indicated, depending on the patient's general condition, pre-existing disorders, and the disease situation. . Check List Cytostatic Treatment Many important pharmacokinetic parameters (e.g., renal function, liver function) correlate particularly with the body surface area (BSA). Therefore, dosage recommendations for cytostatics are generally based on the patient's body surface area (in m2). Height and weight are used to calculate BSA. Body surface area (BSA) calculation is based on empirical formulas: Body Surface Area (m2) = ( Height (cm) × Weight (kg) / 3,600 )0.5 Body Surface Area (m2) = 0.0235 × Height (cm)0.42245 × Weight (kg)0.51456 Simplified formulas are not sufficiently accurate for clinical use and should not be used for calculating the dosage of cytostatics. Sufficiently accurate alternatives used in everyday clinical practice are slide charts, BSA tables, or so called nomograms. Alternatively, many internet pages provide online body surface area calculations or offer BSA calculators for download. In obese patients, various cytostatic dosages have to be adapted to the body weight. Rule of thumb: • With palliative indication: limiting of body surface area-based cytostatic dosage to a maximum of 2 m2 • With curative indication: dosage calculation based on "ideal body weight" (IBW) or "adapted IBW" ( The individual doses of cytostatic drugs should be adapted to the current status of the patient. Primarily, the following parameters should be taken into consideration: hematological situation, liver function, renal function, performance status, expected toxicity (e.g., cardiotoxicity, oto-/ neurotoxicity, mucosal toxicity) and comorbidities. Calculation Creatinine Clearance (ml/min) = Creatinine Urine (mg/dl) × Urine Volume ( The following parameters are used to evaluate liver function: • Bilirubin, alkaline phosphatase • Transaminases (AST, ALT), γGT • Synthetic capacity (coagulation parameters, Quick's test score) Generally, bone marrow toxicity is the dose-limiting side effect of cytostatic treatment (exceptions: bleomycin, vincristine, L-asparaginase). • Whether dose adjustment is necessary or whether it is preferable to extend the treatment interval, has to be decided in each individual case. • In cases of prolonged neutropenia after chemotherapy, the administration of hematopoietic growth factors (e.g., G-CSF) should be considered. • If bone marrow damage / suppression of normal hematopoiesis can be attributed to the primary disease (leukemia, lymphoma with bone marrow involvement, etc.), dose reduction based on blood count parameters is not indicated. Leukocyte count (/µl) Thrombocyte count (/µl) Dose (%) > 3,500 > 100,000 100 3,000-3,500 75,000-100,000 75 2,500-3,000 50,000-75,000 50 < 2,500 < 50,000 0 Phys: Phys: In obese patients, dose adjustment of cytostatics to body weight is required. This is of particular importance for cyclophosphamide and etoposide / VP-16 in the frame of high-dose chemotherapy. • In these cases, dose should be based on the "ideal body weight" (IBW). • If the IBW is more than 15 kg below the real body weight (which is usually the case with highly obese patients), dose adjustment should be based on the "adapted ideal body weight" (AIBW). Decisions on chemotherapy during pregnancy have to be taken on an individual patient basis. The patient and her relatives are to be included in the decision-making process. Of practical importance are, in particular: • Stage of pregnancy • Stage / prognosis of malignancy • Patient's general health / secondary disorders • Therapeutic options • Postchemotherapy fertility / urgency of wanting a child Cytostatic chemotherapy up to the 20th WOG bears a high risk of fetal malformation (15-20%). Termination of pregnancy should therefore be seriously considered. In deciding between abortion and deferment of chemotherapy, the therapeutic situation of both mother and child needs to be taken into consideration. Treatment is absolutely indicated when, due to expected rapid progression (acute leukemia, highly malignant lymphoma), it is unlikely that the mother will survive until the earliest possible delivery date. • As far as possible, deferment of curative chemotherapy should be avoided. • Immediate initiation of treatment after termination of pregnancy. • If the parents object to an abortion, chemotherapy should nonetheless be started immediately (ATTN: with highly elevated risk of malformation). Through frequent sonographic monitoring, malformations can be detected before the 24th WOG and the pregnancy can subsequently be terminated. It is important to inform the patient of the risk of non-detection of malformations by ultrasound examination. Ep: Ep: Prg: Prg: Th: Th: . Chemotherapy During Pregnancy and Lactation • Immediate initiation of treatment after termination of pregnancy. • If in light of the palliative situation immediate treatment is not desired, deferment until completion of organogenesis may be considered. The possible risks for both mother (tumor progression) and child (transplacental tumor metastasis into fetus) must be pointed out. Chemotherapy between the 20th and 32nd WOG rarely leads to fetal malformation. The main therapeutic risks are organ toxicity, intrauterine growth retardation (IUGR) and preterm delivery. Precautions: • Monitoring of pregnancy at a perinatal center • Planning of early delivery • Consideration of possible myelosuppression in both mother and child • Consideration of prenatal surfactant therapy to enhance pulmonary maturation Immediate initiation of chemotherapy. Possible deferment of antineoplastic therapy until infant is viable. Postpartum initiation of treatment. Patient information on risks and possible consequences of therapy delay for both mother (tumor progression) and child (risk of metastasis). Usually, the fetus is viable from the 32nd WOG on → delivery before initiation of chemotherapy. Infants should be weaned before chemotherapy is initiated. For the majority of cytostatic drugs, the transfer into breast milk is not specified. However, potential damage to the child can not be ruled out completely. 3. 4. 6. Web: Physicochemical incompatibility of antineoplastic compounds may lead to, e.g., precipitation, discoloration, decomposition. These processes can be triggered by even brief contact with other compounds, e.g., when using the same infusion pump, injection via a Y-piece, or parallel infusion via a manifold set. In principle, mixing different cytostatic drug solutions as well as mixing cytostatics with parenteral nutrition solutions should be avoided. When using complex therapeutic regimens, manufacturers' recommendations and drug incompatibility databases should be consulted. • Cytostatic drugs and substances listed below are physicochemically incompatible. • Consecutive administration of incompatible compounds without changing the infusion pump or injection via a Y-piece has to be avoided. • Incompatibilities are negligible if the infusion set is replaced before each drug administration or flushed with 0.9% saline or 5% glucose solution. • Drugs not listed in this table cannot generally be seen as compatible. In case of incompatibility questions, the responsible pharmacy should be contacted. Physicians and nurses administrating chemotherapy have the obligation to regularly and carefully check infusions for incompatibilities. Amsacrine Saline and other chlorine solutions, acyclovir, amphotericin B, aztreonam, ceftazidime, ceftriaxone, cimetidine, furosemide, ganciclovir, heparin, methylprednisolone-21-hydrogen succinate, metoclopramide, ondansetron, sargramostim Asparaginase Not specified Bleomycin Aminophylline, amino acids, ascorbic acid, carbenicillin, cefalotin, cefazolin, dexamethasone, diazepam, furosemide, 5% glucose, hydrocortisone-21-hydrogen succinate, methotrexate, mitomycin, nafcillin, penicillin G, riboflavin, sulfhydryl-containing drugs (e.g., glutathione), terbutaline, divalent and trivalent cations Carboplatin Aluminum (e.g., in infusion cannulas), 5-FU, mesna, sodium bicarbonate Carmustine Alkaline solutions, allopurinol, sodium bicarbonate, PVC (infusion container and application set) Amino acids, water for injection, alkaline solutions, aluminum (e.g., in infusion cannulas), amifostine, cefepime, chelating agents (e.g., penicillamine), 5-FU, gallium nitrate, 5% glucose, mesna, metoclopramide, sodium bicarbonate, sodium bisulfite-, -hydrogen sulfite-and -thiosulfate-containing drugs, piperacillin / tazobactam, thiotepa Cladribine 5% glucose Aluminum (e.g., in infusion cannulas), amphotericin B, benzyl alcohol Vinblastine Cefepime, furosemide, heparin, pH < 3.5 or pH > 5 Vincristine Cefepime, doxorubicin, furosemide, idarubicin, sodium bicarbonate, pH < 3.5 or pH > 5 Vindesine 5-FU, sodium bicarbonate, pH < 3.5 or pH > 5 Vinorelbine Acyclovir, alkaline solutions, allopurinol, aminophylline, amphotericin B, ampicillin, cefazolin, cefoperazone, ceforanide, cefotaxime, cefotetan, ceftriaxone, cefuroxime, 5-FU, furosemide, ganciclovir, methylprednisolone-21-hydrogen succinate, mitomycin, sodium bicarbonate, piperacillin, thiotepa, trimethoprim / sulfamethoxazole . Cytostatic Drug Incompatibilities Precautions for the safe handling of cytostatics involve preparation, use, and disposal. Of particular importance is systemic exposure of staff to cytostatics via inhalation, ingestion, and cutaneous absorption. Potential threats include: • Local and systemic toxicity • Acute and chronic toxicity • Genotoxicity / teratogenicity / mutagenicity • Staff safety, occupational health and safety • Patient safety • Product safety • Environmental protection Cytostatics must be prepared and used by trained staff only. Cytostatic drug solutions are prepared in the pharmacy in accordance with the pharmaceutical law, pharmacy rules, and approved principles of pharmaceutical science. Preparations for the use of cytostatics are the responsibility of the physician and are carried out by him-/herself or by members of staff based on approved principles of medical science. Cytostatic drug solutions should be prepared at a central location, e.g., in the hospital pharmacy: • In rooms separated from other sectors, with limited access for authorized staff only. • There must be no eating, drinking, or smoking in the designated rooms. • There must be no other activities taking place in the room during preparation of cytostatics. • Doors and windows must be kept closed during preparation: draft-free work environment. Preparation must be carried out in category 2 safety cabinets. • Safety cabinets are to be regularly inspected in accordance with current policies. Inspections are to be documented in a log book. • A user manual must be provided for work at the cabinets. • The user manual must contain directives for cleaning and disinfection of all work surfaces. • Supply and exhaust air in the preparation room must correspond with the cabinet. The exhaust air ventilation system must be ducted outside. • Air flow modification during work (e.g., covering of ventilation slots, addition of voluminous or large numbers of items to the cabinet, vigorous movements) is to be avoided as it could negatively influence the retention capacity / product safety / entrainment prevention. • Protective clothing is mandatory to avoid direct contact between skin or mucous membranes and cytostatics. • Liquid-proof, long-sleeved, high-necked, non-fuzzing gowns with fitting cuffs. Suitable clothing includes liquid-proof disposable gowns or textile disposable gowns with liquid-proof gauntlets. • Gowns must only be worn within the designated rooms. • Gowns must be changed at least on a daily basis. • Liquid-proof disposable gloves, e.g., latex and/or nitrile gloves of at least 0.2 mm thickness and of documented quality (double gloving recommended). Meth: • Gloves must be long enough to remain tight above the cuff during work. • In the event of visible contamination or leakage and after working with amsacrine, carmustine, irinotecan, mitoxantrone, and thiotepa, gloves must be changed immediately. When handling cytostatics outside the safety cabinet, e.g., to remove a major spillage of cytostatics, protective glasses with side shields must be worn. When handling cytostatics outside the safety workbench, e.g., to remove a major spillage of cytostatics, a particle filtration half-mask must be worn. For easy removal of contamination, cytostatics should be prepared on a liquid-proof absorbent mat. In addition: • Use compresses when opening ampoules. • When retracting cannulas from piercable rubber stoppers or removing residual air from syringes, use compresses or gauze swabs in order to avoid contamination from spraying or aerosol formation. • As far as possible, choose cytostatics in "cytosafe packaging. " • Strict use of disposable syringes and needles with Luer-Lok connections. • Use pressure release devices with filters (spikes) for venting injection bottles. • Cytostatics should be dissolved in a closed system. Cytostatics and solvents or vehicles are transferred between containers using transfer caps or needles, providing internal pressure equalization. That way, containers can be disconnected without pressure differences, preventing splashing or release of cytostatic aerosols. Drug solutions must be transported in shatter-proof, water-proof, and sealable containers. The following factors impact cytostatic drug storage and stability: • Expiry date of primary product (dry substance or solution) • Physicochemical stability of cytostatic stock solution • Physicochemical stability of the ready-prepared cytostatic compound • Hygienic aspects, i.e., microbiological fitness • Cool storage or storage at room temperature • Light protection • Shelf-life of prepared solution • When connecting, changing, venting, or removing an infusion system, contamination of staff members must be avoided (e.g., by wearing protective gloves), as well as contamination of the room and aerosol formation. • For this purpose, technical aids (pressure release systems with aerosol filters) should be used. • Vent the infusion system only with carrier solution. When dispensing drugs into containers designated for patients (e.g., dispenser), certain precautions have to be observed, e.g.: Pharmacology and Pharmacotherapy • Wearing of protective gloves • Use of tweezers or spoons • Splitting of tablets, pulverization, etc. should be carried out using suitable aids (closed systems) and with particular care (preparation usually in the pharmacy). • When cleaning and handling containers and items used for dispensing drugs, contamination of staff members must be avoided. Full details should be given in a user manual. Use suitable protective gloves or applicators. Spilled cytostatics must be removed immediately and carefully and in compliance with the preventive measures specified for the preparation of cytostatics: • When lifting contaminated broken glass use an extra pair of gloves to prevent physical risks. Preferably, lift shards with tongs. • Use dry disposable cloths to soak up spilled solutions. • Use wet disposable cloths for spilled powder. • Afterwards, clean with soapy water. • Dispose of all contaminated materials using a leak-proof single-use container. • Sets of the necessary equipment (protective gown, safety goggles, gloves and masks, cellulose, waste container, scoop) -including instructions -should be held ready. Areas of skin contaminated with cytostatics must be irrigated immediately with copious quantities of cold water. In case of eye contamination, irrigate with copious quantities of water or isotonic saline solution for 10 min. Then, consult an ophthalmologist. Cytostatics are collected and disposed of according to local regulations. • Collection and disposal of cytostatic residue requires particular supervision and is to be carried out in accordance with waste regulations and the Hazardous Substances Ordinance using labeled, robust, and leak-proof containers. • Collection should be separate and in a central location. Disposal should be carried out in hazardous waste incinerators. • Materials contaminated with cytostatics (textile aids, disposable gowns, applicators, etc.) can be treated as household waste. • Contaminated reusable clothes or reusable textile materials must be changed, collected without further manipulation, and laundered. • Cytostatics-containing excrements are not regarded hazardous but should be disposed of on the ward in compliance with hygiene guidelines and health and safety regulations. Specific hormonal effects following interaction with cell-surface receptors, e.g., estrogen / progesterone / steroid receptors. Inhibition of specific hormonal effects via: • Administration of hormonally active compounds → suppression of endocrine regulatory systems • Application of specific inhibitors (e.g., competitive inhibition of hormone receptors) Pharm: . Hormone Therapy Hormone Therapy Buserelin GnRH / LHRH analog with continuous stimulation of pituitary receptors → desensitization of pituitary gland → LH / FSH secretion ↓ → estrogen / testosterone synthesis ↓ ("drug-induced castration") • Subcutaneous injection every 3 months, one applicator with 9.45 mg (corresponding to 3 implant rods) • ATTN: short initial stimulation of estrogen or testosterone excretion, prior to hormone blockage → simultaneous antiestrogen / antiandrogen treatment for initial 3-4 weeks recommended . Hormonal Treatments Part Pharmacology and Pharmacotherapy Goserelin 1-(5-Oxo-l-prolyl-l-histidyl-l-tryptophyl-l-seryl-l-tyrosyl-l-O-tert-butyl-d-seryl-l-leucyl-l-arginyl-l prolyl)semicarbazide, GnRH analog Subcutaneous injection monthly 3.6 mg, or every 3 months 10.8 mg ATTN: short initial stimulation of estrogen or testosterone excretion, prior to hormone blockage → simultaneous antiestrogen / antiandrogen treatment for initial 3-4 weeks recommended . Hormonal Treatments Part Pharmacology and Pharmacotherapy Leuprorelin 5-Oxo-l-prolyl-l-histidyl-l-tryptophyl-l-seryl-l-tyrosyl-d-leucyl -l-leucyl-l-arginyl-N-ethyll-prolinamide, GnRH analog . Hormonal Treatments Pharmacology and Pharmacotherapy Part 0 Intercellular mediators synthesized by immune cells and mesenchymal cells (fibroblasts, endothelial cells, stroma cells) which modulate immune responses, cellular proliferation, and differentiation. Characteristics: • Soluble proteins or glycoproteins, 15-40 kDa molecular weight • Pleiotropic, overlapping, and/or synergistic effects Def: Interleukins ( . Cytokines Interferons ( Interferon α (IFNα) Type 1 interferon, "leukocyte interferon"; glycoprotein, > 20 variants, 156-172 amino acids, 19-26 kDa. Peginterferon is a polyethylene-glycol conjugated form with an increased half-life. • Gene locus: chromosome 9p22, variable expression of IFNα variants • Expression: leukocytes, monocytes / macrophages, B-lymphocytes, fibroblasts All IFNα types display antiviral, antiparasitic, and antiproliferative activity: • T-cells: T-suppressor activity, activation of cytotoxic T-cells, TH1 induction • Modulation of B-and NK cell function, monocyte activation / macrophages • Antigen expression ↑, oncogene expression ↓, inhibition of angiogenesis . Cytokines Since 1998, several different monoclonal antibodies have been licensed for treatment of solid tumors and hematological neoplasias. Application as monotherapy or in combination, e.g., with chemotherapy. Antibodies are usually specific for each species. Application of murine antibodies in humans might lead to loss of effect due to generation of antibodies as well as to incompatibility reactions. Several different types of antibodies with human parts are clinically used: • "Chimeric" antibodies: constant region of human origin, variable region (including antigenbinding site) of primary species of origin • "Humanized" antibodies: antigen-binding region of primary species of origin, remainder of human origin (95%) • "human" antibodies: 100% human sequence . Humanized, recombinant, monoclonal IgG1-κ antibody (mouse / human), selectively binding with high affinity to the extracellular domain of the human epidermal growth factor receptor 2 (EGF-R2, HER2) • HER2 protooncogene encodes the transmembrane receptor protein p185 (185 kD, HER2/neu) with intrinsic tyrosine kinase activity. HER2 overexpression in 25-30% of primary breast cancer and in other epithelial neoplasias, e.g., non-small cell lung cancer, bladder / gastric / ovarian / prostate cancer • Specific binding of trastuzumab to extracellular domain of p185 → complement-mediated cytotoxicity (CDC) and antibody-mediated cytotoxicity (ADCC), apoptosis induction, inhibition of signal transduction, receptor downregulation, cell cycle arrest . Monoclonal Antibodies In addition to therapeutically used antibodies (7 Chap. 3.5), low molecular weight antineoplastic compounds specifically binding to biologically relevant target structures are also classified as "targeted therapies. " The identification of classic cytostatic drugs was based on a multitude of empirical studies ("screening") in tumor model systems (e.g., murine tumors). In contrast, the development of "targeted therapies" is based on the knowledge of pathogenesis and pathophysiology of malignant diseases ("rational drug design"). Main approaches: • Modification of gene function: gene therapy, antisense oligonucleotides, ribozymes • Modification of protein function: monoclonal antibodies, receptor antagonists, binding proteins, angiogenesis inhibitors • Specific toxic effect: combination of specific "cognition" molecules (e.g., receptor ligands, monoclonal antibodies) and toxins (synthetic or natural toxins), so-called "drug targeting", e.g., with immunotoxins Signal transduction inhibitors inhibit specific protein kinases, other enzymes or effector molecules of intracellular signal transduction. The effects of specific inhibitors depend on the cellular target structures. Molecules targeting different structures are used in preclinical and clinical trials. Regulation of angiogenesis VEGF, angiopoietin, tie, HIF Regulation of apoptosis TRAIL-R1, bcl-2, p53, NFκ-B, PI3-kinase, ubiquitin Oncogenes ras, raf, jun, fos, kinases Regulation of proliferation Growth factors, e.g., EGF, IGF Signal transduction Tyrosine kinases (EGF-R, VEGF-R, PDGF-R), serine-threonine kinases (TOR) Cell cycle regulation Cyclins, cyclin-dependant kinases (CDK), mitotic kinases VEGF vascular endothelial growth factor, HIF hypoxia-inducible factor, TRAIL tumor necrosis factor-related apoptosis-inducing ligand, NFκ-B nuclear factor kappa B, PI3 phosphatidylinositol-3, EGF epidermal growth factor, IGF insulin-like growth factor, PDGF platelet-derived growth factor, TOR target of rapamycin Kinases are enzymes which phosphorylate specific substrates (e.g., tyrosine residues). Tyrosine kinases play an important role in signal transduction. Differentiation between: • Receptor tyrosine kinases • Intracellular tyrosine kinases Tyrosine kinase inhibitors are the most important clinically used "targeted therapies. " 0 Part Pharmacology and Pharmacotherapy Bexarotene 0 Pharmacogenetics: study of genetic factors determing efficacy and safety of drugs Pharmacogenomics: study of the entire spectrum of genes which can influence pharmacodynamics and pharmacokinetics of specific drugs • Genotyping of "single nucleotide polymorphisms" (SNPs): selective genetic polymorphisms impact the activity of key proteins essential for drug response and drug metabolism. With some cytostatics, SNPs allow rational predictions about response and toxicity. • Gene expression analysis (7 Chap. 2.3): global gene expression analysis using DNA arrays → genetic determinants of efficacy and toxicity of chemotherapeutics can be empirically identified. The term pharmacogenomics encompasses not only the influence of gene expression on a drug, but also the effect drugs have on the gene expression pattern. • Drug development: identification of potential targets for new drugs. Identification of genetic determinants of efficacy and toxicity of chemotherapeutics is useful if the following conditions are met: • Wide interindividual differences in pharmacokinetic parameters (e.g., oral bioavailability, half-life, etc.) • Bimodal AUC distribution ("area under the curve") for the concentration-time curve of active metabolites • Occurrence of severe toxicities, with lack of dose-response relationship . Pharmacogenetics and Pharmacogenomics Monoclonal immunoglobulin preparations with specific effects directed against defined target structures (antigens) Antibody Nomenclature Notations for monoclonal antibodies consist of several components and follow internationally valid systematics. In general, they are formed by one prefix and three suffixes (according to the following pattern col"), mammary ("ma"), testis ("got"), prostate ("pr" / "pro"), cardiovascular ("cir"), viral ("vir"), immune system mab" indicating a monoclonal antibody or antibody fragment Example: Alem-tu-zu-mab: humanized antibody against an antigen that is expressed by different malignant tumors Potential Mechanism of Action of Monoclonal Antibodies • Competitive receptor blockade → blockage of receptor-mediated effects (e.g., inhibition of cytokines or growth factors) • Receptor activation → induction of receptor-mediated effects (e.g., apoptosis induction) • Complement activation and complement-mediated cytotoxicity (CDC) • Antibody-mediated cellular cytotoxicity radioimmunoconjugates") or cytotoxic components Monoclonal antibodies directed at growth factor receptors Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis ERBB receptors and cancer: the complexity of targeted inhibitors The clinical use of antibodies in haematological malignancies Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia Development trends for monoclonal antibody cancer therapeuties Mechanism of action and resistance to monoclonal antibody therapy Immunotoxin conjugate, humanized, recombinant, monoclonal IgG4-κ antibody specifically binding to the antigen CD33, conjugated with the cytostatic antibiotic calicheamicin • Binding to CD33 on leukemic myeloblasts and myeloid cells (myelomonocytic progenitors, neutrophils, erythrocytes, thrombocytes, monocytes / macrophages) • Internalization of CD33 with gemtuzumab ozogamicin → release of calicheamicin derivatives in lysosomes → DNA strand breaks → cytotoxic effect antibody-mediated cytotoxicity (ADCC), apoptosis induction median serum half-life t½ of gemtuzumab ozogamicin 45-60 h, t½ of unconjugated calicheamicin 100 h • Metabolism: internalization and hydrolysis, hepatic and renal elimination • Bone marrow: severe myelosuppression (neutropenia, thrombocytopenia, anemia), bone marrow recovery after approximately 40 days. Infections due to neutropenia (50%), hemorrhages (15% of cases, cerebral, gastrointestinal, epistaxis, hematuria diarrhea (40%), constipation, abdominal pain, loss of appetite • Liver: transient increase of transaminases, cholestasis (25%), hyperglycemia • Skin: local reactions, erythema, pruritus, petechiae • Infusion-induced reactions ("cytokine release syndrome"): fever (85%), chills (75%), hot flushes, sweat, erythema, urticaria, hypo-or hypertension, dyspnea • Other risk of infusion-induced reactions including fever, chills, thrombocytopenia, hypotension, tumor lysis syndrome. Premedication with paracetamol 500-1000 mg p.o. and antihistamines (e.g., clemastine 2 mg i B-cells and 95% of malignant B-NHL) → complementmediated cytotoxicity (CDC) and antibody-mediated cellular cytotoxicity (ADCC), apoptosis induction, depletion of CD20-positive lymphocytes → B-cell depletion, serum immunoglobulins ↓, commencing regeneration after 2 weeks, complete reconstitution after 9-12 months • Direct antiproliferative effect against malignant B-cell lines shown in vitro • Sensitization h, after fourth infusion t½ 190-200 h. Pronounced intra-and interindividual variability of serum concentration, detection of rituximab in serum 3-6 months after treatment possible • Metabolism: proteolysis • Bone marrow: lymphopenia (50%), marginal myelosuppression • Cardiovascular: hypotension, hypertension, arrhythmia, rare cuses of angina pectoris, cardiac insufficiency, myocardial infarction, mainly with pre-existing heart disease • Pulmonary: cough, dyspnea, sinusitis, bronchitis, bronchiolitis obliterans cytokine-release syndrome"): fever (50%), chills, rigor, rhinitis, conjunctivitis, sore throat, bronchospasm, angioedema • Other: infections, night sweat, fatigue, reduced performance status, edema, arthralgia, myalgia, skeletal pain, hypercalcemia, LDH ↑, lymphadenopathy, coagulation disorders, dysgeusia, tumor lysis syndrome • Hypersensitivity to murine proteins, severe pre-existing cardiac disease Approved indications for use: refractory / relapsed B-cell lymphoma Clinical trial use: multiple myoma, ITP, rheumatoid arthritis, autoimmune disease Dosage and application: • 375 mg/m2/day i.v. weekly with monotherapy, in combination with CHOP on day 1 of each cycle • ATTN: infusion-induced reaction prophylaxis: premedication with paracetamol 500-1,000 mg p.o. and clemastine 2 mg i.v., slow increase of infusion rate (initially 50 mg/h, gradually increasing up to maximum 400 mg/h). Close monitoring. Discontinue antihypertensive medication 12 h before treatment • ATTN: in case of high tumor load (lymphomas > 10 cm, lymphocytosis > 50,000/µl, leukocytosis > 50 competitive inhibition of EGF-R tyrosine kinase, signal transduction ↓ • Receptor internalization and downregulation • Antibody-mediated cytotoxicity, apoptosis induction, tumor neoangiogenesis ↓ • Inhibiting tumor growth and metastasis Efficacy of panitumumab monotherapy in metastatic colorectal carcinoma is increased with expression of the wild-type KRAS gene. Tumors with expression of mutated KRAS show reduced response rates. KRAS status should be considered in selecting patients with metastatic colorectal carcinoma as candidates for panitumumab therapy Kinetics: elimination half life (t½): 7.5 days (3.6 -10 • Pulmonary: dyspnea, cough, pulmonary fibrosis (rare) constipation, abdominal pain, mucositis • Skin: acneiform skin rash, pruritus, erythema, exfoliation, nail disorders, dry skin • Other: fatigue, reduced performance status, infections, peripheral edema, hypomagnesemia Pregnancy, lactation Indications for use: metastasized colorectal carcinoma Clinical trial use: breast cancer, non-small cell lung cancer Dosage: of EGFR and KRAS status in tumor tissue recommended prior to treatment reduced risk of infusion-reduced reactions as compared to other EGFR inhibitors, due to fully human nature of the antibody Clinical anticancer drug development: targeting the cyclin-dependent kinases The development of imatinib as a therapeutic agent for chronic myeloid leukemia Specific Protein Kinase Inhibitors Targeting apoptosis pathways in cancer therapy Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy Proteasome inhibitors: antitumor effects and beyond Insulin-like growth factors and neoplasia pentamethyl-2-naphthalenyl)-ethenyl]benzoic acid • Selective activation of retinoid X receptors (RXR) α, β, and γ → Activated receptors function as transcription factors → Impact on apoptosis, cellular proliferation and differentiation • Growth inhibition of specific malignant cells lines in vitro and vivo • Kinetics: moderate oral absorption, peak plasma levels reached after 2 h, plasma protein binding > 99%, terminal half-life t½ 7 h • Metabolism: hepatic degradation via cytochrome P450 system (CYP3A4) and glucuronidation, hepatobiliary elimination • Bone marrow: leukopenia, neutropenia, anemia • Cardiovascular: peripheral edema • Pulmonary: dyspnea, cough, pneumonia • Gastrointestinal: nausea, vomiting, diarrhea, abdominal pain • Liver / pancreas: transient elevation of transaminases, cholestasis, lipid abnormalities (triglycerides ↑, cholesterol John's wort) are expected to decrease bexarotene plasma concentrations • Effects of insulin may be enhanced → risk of hypoglycemia • Hypersensitivity to retinoids, pregnancy, lactation • Relative CI: patients with risk factors for pancreatitis Approved indications: cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) Clinical trial use: head and neck cancer, NSCLC, renal cell carcinoma, Kaposi's sarcoma Dosage: oral application (300 mg/m2/day p.o.) or topical application • ATTN: bexarotene may cause fetal harm when administered to pregnant women. Appropriate precautions should be taken to avoid pregnancy and fathering • BEFORE TREATMENT: full blood count, hepatic and renal function tests, thyroid function pyrazinylcarbonyl)amino]-propyl]amino]butyl]boric acid • Reversible inhibitor of 26S-proteasome → inhibiting degradation of ubiquitinated proteins → apoptosis induction in cells with bcl-2 overexpression, angiogenesis inhibition, IL-6 mediated effects ↓, adhesion molecules ↓ marrow: neutropenia, anemia orthostatic hypotension, syncope, hypertension, arrhythmia, cardiac failure, myocardial infarction • Gastrointestinal tract: diarrhea (dose-limiting, 51%), nausea (65%), vomiting, abdominal cramps, loss of appetite • Kidney: renal function disorders, electrolyte disorders (rare) • Nervous system: peripheral neuropathy (dose-limiting), headaches, drowsiness • Other: fever, fatigue, reduced performance status (65%), arthralgia, myalgia, conjunctivitis, hyperbilirubinemia CYP3A4) inhibiting substances (ketoconazole, itraconazole, voriconazole, erythromycin, clarithromycin) → bortezomib concentration ↑ no simultaneous administration of phenprocoumon (metabolization via CYP2C9) → patients with anticoagulation therapy should switch to low molecular weight heparin • Hypersensitivity to bortezomib, boric compounds, or mannitol • Pregnancy, lactation • Cardiac or neuropathic disorders Indication: multiple myeloma, cutaneous T-cell lymphoma Clinical trial use: solid tumors Dosage: 1.3 mg/m2/day i Inhibiting proliferation / apoptosis induction in Philadelphia-positive CML and ALL by inhibiting BCR-ABL fusion protein and in gastrointestinal stromal tumors (GIST) by inhibiting c-kit-protein (CD117, stem cell factor receptor) Kinetics: oral bioavailability, plasma protein binding 93-96%, median half-life t½ 3-5 h • Metabolism: hepatic inactivation (cytochrome P450 3A4) and elimination (glucuronidation) • Bone marrow: neutropenia, thrombocytopenia (48-83%), impaired thrombocyte function, anemia • Cardiovascular: QT elongation • Gastrointestinal: nausea, vomiting, abdominal pain, diarrhea, loss of appetite Liver: transient increase of transaminases, cholestasis • Nervous system: headaches, somnolence, insomnia • Skin: dermatitis, exanthema, pruritus, alopecia • Other: fluid retention (50%, with effusions, peripheral edema, pulmonary edema), dyspnea, fever, fatigue, reduced performance status CYP3A4) inhibiting substances (ketoconazole, itraconazole, voriconazole, erythromycin, clarithromycin) → dasatinib concentration ↑ John's wort) → effect of dasatinib ↓ with QT elongation, hypokalemia, hypomagnesemia, therapy with antiarrhythmics Indications: CML, Ph+ ALL, if refractory to primary treatment Dosage: • 140 mg/day p.o N-(3-ethynylphenyl-)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine • EGFR (epidermal growth factor receptor) expression on solid tumors, especially with nonsmall cell lung cancer, esophageal carcinoma, head and neck tumors, renal cell carcinoma, gastrointestinal carcinoma, breast cancer • Inhibiting epidermal growth factor receptor type 1 (HER1/EGFR1) tyrosine kinase → inhibiting EGFR activation / signal transduction → 3A1/1A2) and renal excretion • Pulmonary: dyspnea, cough, interstitial pneumonia, pneumonitis, bronchiolitis obliterans, pulmonary fibrosis • Gastrointestinal: nausea, vomiting, abdominal pain, diarrhea, loss of appetite, gastrointestinal hemorrhages • Liver: transient increase of transaminases, cholestasis, impaired coagulation • Nervous system: headaches • Eyes: conjunctivitis, keratitis, visual disturbances, lacrimation ↑ • Skin: erythema (70%), dermatitis, exanthema, pruritus • Other: fatigue John's wort) → effect of erlotinib ↓ • ATTN: do not use phenprocoumon with erlotinib due to metabolization by CYP2C9. Anticoagulated patients should receive low molecular weight heparin Hypersensitivity, pregnancy, lactation, impaired liver function Approved indications (USA): non-small cell lung cancer, pancreatic cancer Clinical trial use: solid tumors . Chem: MOA: Pkin: Se: DDi: Ci: Th: . Targeted Therapies Ref: Web: Pharmacogenetics of 6-mercaptopurine (6-MP) At the cellular level, 6-mercaptopurine (6-MP) is converted into 6-thioinosine monophosphate (6-TIMP) and 6-thioguanine triphosphate nucleotide (TGN). The incorporation of 6-TGN into DNA mediates the antileukemic activity of At the same time, steps of deactivation take place. How much 6-MP can be activated in the bone marrow depends on the extent of deactivating methylation by thiopurine methyltransferase • Patients with genetic deficiency in TPMT accumulate 6-TGN to toxic concentrations, leading to severe and prolonged myelosuppression. Due to the long latency period of this toxicity TPMT*2, TPMT*3A, and TPMT*3C are responsible for 80-95% of the phenotype in TPMT deficiencies. Patients with the wildtype genotype show high TPMT activity. Patients who are heterozygous or homozygous for variant alleles display medium or low enzyme activity With a frequency of 3-6%, it is the most prevalent variant amongst the Caucasian population. TPMT*3A was found in 55% of patients with a phenotype for this enzyme deficiency Pharmacogenetic testing: proofs of principle and pharmacoeconomic implications Pharmacogenomics: roads to anticancer therapeutics nirvana? Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development Pharmacogenetics and proteomics of anticancer drugs in non-Hodgkin's lymphoma Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia Pharmacogenetic influences on treatment response and toxicity in colorectal cancer Pharmacogenomics: from bench to bedside Hormone-sensitive neoplasias (verified receptor expression): • Breast cancer (antiestrogens, gestagens, LHRH analogs) • Prostate cancer (estrogens, antiandrogens, LHRH analogs) • Carcinoma of the uterine corpus (antiestrogens) • Thyroid carcinoma (thyroxine for TSH suppression, also: substitution therapy) • Lymphomas, multiple myeloma (corticosteroids) • Carcinoid tumors (octreotide) For therapy details, see respective chapters. Use of hormones to replace hormone production which has completely or partially ceased as a result of antineoplastic therapy.• Estrogen / gestagen preparations in cases of premature menopause following chemotherapy • Testosterone after bilateral orchiectomy • Thyroxine after thyroidectomy • Cortisone after bilateral adrenalectomy (e.g., due to bilateral adrenal tumors) In women, chemotherapy and high-dose chemotherapy in particular, can lead to gonadal damage with subsequent estrogen deficiency and premature menopause. Risks include: • Menopausal symptoms • Osteoporosis • Cardiovascular complications Estrogen substitution may be indicated in women with early menopausal symptoms and evidence of reduced hormone levels (estrogen).ATTENTION: Continuous estrogen and combined (estrogen + gestagen) therapy constitutes an increased risk of breast cancer and cardiovascular events in healthy menopausal women (WHI study) . Treatment should only be initiated after careful evaluation of risks and benefits as well as detailed patient information.Side effects of long-term estrogen substitution: • Thrombosis, thromboembolism, cardiovascular events • Increased breast tissue density → reduced sensitivity for mammography • Increased risk for relapse of breast cancer and endometrial carcinoma Alternatives to estrogen substitution: • Osteoporosis: bisphosphonates, tamoxifen, selective estrogen receptor modulators (e.g., raloxifene) • Cardiovascular prevention Testicular carcinoma initially requires unilateral orchiectomy. Loss of the contralateral testicle due to unrelated causes or a second metachronous testicular carcinoma results in anorchia with subsequent testosterone deficiency.Testosterone therapy has no influence on prognosis and progression of testicular carcinoma → long-term testosterone replacement after bilateral orchiectomy definitely indicated. Thyroid carcinoma commonly requires total thyroidectomy with life-long thyroid hormone replacement (L-thyroxine).Administration of high dose of L-thyroxine (175-250 µg/d). • Inflammation mediator (mainly in lung) • Hematopoiesis: synergistically with other cytokines, stimulation of megakaryopoiesis, erythropoiesis, myelopoiesis, lymphopoiesis, and (in vitro) bone marrow stroma cells, increase of thrombocytes usually 5-9 days after application • Gastrointestinal: in vitro inhibition of the proliferation of intact crypt stem cells, in vivo stimulation of proliferation / apoptosis inhibition in damaged crypt cells • Other: adipogenesis inhibitor, modulator of the metabolism of extracellular matrix (fibrosisenhancing) • Inhibition of the Bcr-Abl fusion protein (tyrosine kinase) in Philadelphia chromosome positive CML and ALL cells → proliferation inhibition and apoptosis induction • Inhibition of the c-kit protein (CD117, stem cell factor receptor SCF-R, tyrosine kinase) in gastrointestinal stromal tumors (GIST) • Inhibition of the activated PDGF receptor (platelet-derived growth factor receptor) Multikinase inhibitor, N-[2-(diethylamino) ethyl]-5-[(z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidin)methyl]-2,4-dimethyl-1H-pyrrol-3-carboxamide• Inhibition of > 80 tyrosine kinases, including PDGF receptors α and β, VEGF receptor 1-3, SCF receptor (kit), FLT-3, CSF-1 receptor, and GCDNF receptor (RET) • Inhibiting signal transduction of VEGF (vascular endothelial growth factor) → angiogenesis inhibition → inhibiting growth of angiogenesis-dependent solid tumors Clinical development of a drug takes place after completion of preclinical development and involves a series of clinical trials and defined test phases. It should be conducted in accordance with:• Ethical principles (Declaration of Helsinki, local ethics commission) • Legal regulations (e.g., pharmaceutical law, administrative regulations) • "Good clinical practice, " GCP (international GCP guidelines of the "International Conference on Harmonization, " ICH-GCP) • "Good manufacturing practice, " GMP • "Good laboratory practice, " GLP Adequate statistical methods and scientifically accurate analysis of results are essential for the design and evaluation of clinical studies of all phases. • Chemical / biochemical / biotechnological development • Pharmacological evaluation, stability • Toxicology: acute toxicity, long-term toxicity, carcinogenic / mutagenic / teratogenic effects in animal models • Preclinical in vitro and in vivo efficacy testing • "First in human" testing after successful preclinical development. • In the majority of clinical settings, phase I trials are conducted with healthy volunteers at specific clinical research organizations (CROs). However, due to the potential for side effects (e.g., cytostatic toxicity), classic oncological phase I trials are frequently conducted in hospital units, providing experimental treatment to inpatients. • Clinical studies after drug has been licensed • Primary objective: efficacy in particular situations, rare side effects and interactions, rare contraindications • Pharmacovigilance: continuous monitoring of drug-related adverse reactions at national and international Regulatory Authority level as well as by the manufacturer "Good clinical practice" (GCP) refers to international ethical and scientific standards that must be complied with when planning, executing, and documenting clinical studies with human beings. The confidentiality of records that could identify subjects should be protected, respecting the privacy and confidentiality rules in accordance with the applicable regulatory requirement(s) • Investigational products should be manufactured, handled, and stored in accordance with applicable good manufacturing practice (GMP). They should be used in accordance with the approved protocol • Systems with procedures that assure the quality of every aspect of the trial should be implemented • The medical care given to, and medical decisions made on behalf of subjects should always be the responsibility of a qualified physician or, when appropriate, of a qualified dentist • Each individual involved in conducting a trial should be qualified by education, training, and experience to perform his or her respective task(s) • Formation of inactive 5-fluoro-5,6-dihydrouracil (5-FUH2) by dihydropyrimidine dehydrogenase (DPD) is the rate-limiting step in the catabolism of 5-FU. • The antineoplastic effect of 5-FU in the tumor cell is mediated by the active metabolite 5fluorodeoxyuridine monophosphate . FdUMP is formed in two steps, involving thymidine phosphorylase (TP) and thymidine kinase (TK). Inhibition of thymidylate synthase (TS) by 5FdUMP represents the critical step of 5-FU cytotoxicity. TS catalyses the transformation of dUMP into deoxythymidine 5' monophosphate (dTMP), which is the rate-limiting step of DNA synthesis. TS inhibition depends on the cofactor 5,10-methylenetetrahydrofolate (CH2THF) which forms a ternary complex with 5-FdUMP and TS. • A defect in the catabolic enzyme DPD, which occurs in its complete form in 0.1% of patients and in its partial form in 3-5% of patients, triggers a life-threatening toxic syndrome encompassing severe myelotoxicity, neurotoxicity, and gastrointestinal toxicity. • The DPD genotype has an autosomal recessive pattern of inheritance. An allelic inactivation leading to 50% reduction of normal DPD activity is sufficient for the development of 5-FU toxicity. At least 20 mutations have been found in the DPD coding region and promoter. Two mutations with proven clinical relevance are DPYD*2A and DPYD*9A. DPYD*2A is a splice site mutation resulting in the production of shortened mRNA. DPYD*9A is a common missense T85C mutation in exon 2, leading to a C29R amino acid exchange. Correlation between the two mutations and the clinical phenotype together with other SNPs in enzymes of the 5-FU metabolism should yield improved prediction of 5-FU-associated toxicity.